Richa Sharma/X
Sep 3, 2025, 12:48
Richa Sharma Shares ARCADIA Post-Hoc Findings: Apixaban Prevents Recurrent Stroke in ESUS Patients with LV Dysfunction
Richa Sharma, Associate Professor of Neurology at Yale School of Medicine, has shared a post on X:
“Lower risk of recurrent stroke among patients with ESUS and left ventricular dysfunction randomized to apixaban in the ARCADIA trial in our post-hoc analysis.”
Title: Lower risk of recurrent stroke among patients with ESUS and left ventricular dysfunction randomized to apixaban in the ARCADIA trial in our post-hoc analysis.
Authors: Richa Sharma, Dinesh Jillella, Cenai Zhang, Mitchell S.V. Elkind, Hooman Kamel, Marco R. Di Tullio, Richard A. Kronmal, Balaji Krishnaiah, Shadi Yaghi, W.T. Longstreth Jr, David Tirschwell, Alexander Merkler, Fadi Nahab
Read the full article here.
Find similar posts on Hemostasis Today.
-
Jul 5, 2026, 16:42Marta Sobas: Advancing Pregnancy Care in Myeloproliferative Neoplasms in IHEM
-
Jul 5, 2026, 15:19Marc Carrier: Celebrating 25 Years of Excellence in Thrombosis Training at ISTH 2026
-
Jul 5, 2026, 15:10Arthur Allen: Grateful for the Opportunity to Participate to Enhancing DOAC Surveillance in Acute Care
-
Jul 5, 2026, 15:03Lin Fung Elected The New President of The ISBT – University of the Sunshine Coast
-
Jul 5, 2026, 14:53Angie Read: How Purpose Helps Shape Life After Stroke
-
Jul 5, 2026, 14:46Yomna Maarouf: Should All Adolescent Girls Be Screened for Iron Deficiency?
-
Jul 5, 2026, 14:42Ahmed Mohsen: How Well Do You Know Pulmonary Embolism?
-
Jul 5, 2026, 14:35Vera Ignjatović: Looking Forward to AI in Thrombosis and Hemostasis Session at ISTH 2026
-
Jul 5, 2026, 14:25The Folding Pathway That Shapes Prothrombin Function – JTH